尊敬的Chrome用戶,由于舊版本與本站存在兼容問題,如訪問崩潰,請使用Firefox或IE訪問,亦可更新最新版Chrome。
客服郵箱:[email protected]
深圳南北醫藥有限公司
SHENZHEN NABER MEDICINE CO., LTD

深圳市南北醫藥有限公司成立于1987年,在醫藥行業發展已有三十余載,主要業務涉及藥品、醫療器械代理、專業配送、批發分銷和藥店連鎖經營等;我司被廣東省食品藥品監督管理局批準為深圳市麻醉藥品、第一類精神藥品的經營企業之一(全深圳市僅有兩家企業具有該類藥品的經營資質)。


經過歷年來的辛勤努力,我司在原有的基礎上不斷發展壯大,先后在深圳全資注冊成立了深圳市南北藥行連鎖有限公司、深圳市利物蒲醫療器械有限公司,南北藥行全資收購深圳市寶華藥行連鎖有限公司、深圳市健華藥行連鎖有限公司,并在廣州、東莞、惠州、江門和粵西等地區均設有分、子公司及辦事處,下屬分店有1005家,主要分布在深圳市、廣州市、東莞市、惠州市、江門市和粵西地區等;其中深圳市零售藥店633家(福田區51家;羅湖區41家;鹽田區20家,南山區53家;寶安區187家;龍華新區112家;龍崗區101家;公明新區46家;坪山新區22家);現有員工5000多人,內設行政人力資源部、財務部、質管部、商采部、醫療機構事業部、營運部、新藥部、處方藥(醫院)營運部、器械部、中藥部、信息部、配送中心等12個職能部門。到2018年止,公司及其子公司分別獲得“全國醫藥商業企業100強”和“全國藥品連鎖零售50強”、深圳市“信譽好商店”、“深圳市連鎖經營20強企業”和“中國藥店連鎖行業十大競爭力品牌”等殊榮。家喻戶曉、歷史悠長的品牌,成熟穩定的經營班子,規模化的門店數量,優質的服務、產品質量,與時俱進的公司戰略都是我司極具優勢的核心競爭力。


2017年,我司總銷售額18.3億元,其中總部銷售額8.3億元,分店銷售額為10億元;2018年,我司總銷售額19.8億元,其中總部銷售額8.8億元,分店銷售額為11億元。2019年實現銷售額22億元。為加快公司的發展速度,公司已引入中信建投對公司進行首輪戰略投資;今年深創投、高瓴資本、恒大人壽、招商資本等六大投行也計劃進行B輪投資。計劃未來五年引入資本市場投資總額20億元,在國家十三五“健康中國”的 宏偉戰略指引下,面對大健康、大醫療、新一代互聯網的市場環境,我司將通過引入戰略資本和轉變傳統的經營模式,全力發展藥品連鎖零售業,并突破傳統的藥店經營理念和方式,引入新一代互聯網和人工智能平臺,打造具有南北特色的 “智能藥店”和“智慧社區家庭健康服務平臺”,并計劃到2022年在全省乃至全國設立分公司十家,新增零售連鎖藥店3500家,實現零售規模達70億元。屆時在國內A股主板或香港主板市。

 

 

 

深圳市南北醫藥有限公司

2020217



SHENZHEN NABER MEDICINE CO.,LTD,founded in 1987, has developed in the pharmaceutical industry for more than 30 years,and our main business involves pharmaceuticals, medical device agents, professional distribution, wholesale distribution, and pharmacy chain operations.Our company has been allowed by Guangdong Food and Drug Administration to manage narcotic drugs and first-class psychoactive drugs which just only two companies in Shenzhen have the qualifications to manage such drugs.


        After years of hard work, our company has continued to grow and develop on the original basis, we has registered SHENZHEN NABER PHARMACY CHAIN CO.,LTD, SHENZHEN LIWUPU MEDICAL DEVICES CO.,LTD,acquired SHENZHEN BAOHUA PHARMACY CHAIN CO.,LTD and SHENZHEN JIANHUA PHARMACY CHAIN CO.,LTD....and set up branches, subsidiaries and offices in cities such as Guangzhou, Dongguan, Huizhou, Jiangmen and the west Guangdong, with 1005 affiliated branches Stores, mainly distributed in Shenzhen, Guangzhou, Dongguan, Huizhou, Jiangmen, and wester the Guangdong; among them, there are 633 retail pharmacies in Shenzhen (51 in Futian District; 41 in Luohu District; 20 in Yantian District, Nanshan District) 53; Baoan District 187; Longhua  District 112; Longgang District 101; Gongming District 46; Pingshan District 22); Existing staff of more than 5,000 people, twelve functional departments including administrative&human resources department, finance department, quality control department,commercial Procurement department,medical institution department,chain operation department, new drug department, prescription drug (hospital) operation department, medical device department, traditional Chinese medicine department,information department,and distribution center. As of 2018, the company and its subsidiaries were awarded the "Top 100 Pharmaceutical Commercial Enterprises in China" and "Top 50 National Drug Chain Retailers", "Reputable Stores in Shenzhen", "Top 20 Chain Stores in Shenzhen" and "China Top ten competitive brands in the pharmacy chain industry" and other awards. A well-known and long-established brand, a mature and stable business team, a large number of stores, high-quality services, product quality, and the strategy of advancing with the times,are all core advantages of our company.


         In 2017, our company's total sales were 1.83 billion yuan, of which headquarters sales were 830 million yuan and branch sales were 1 billion yuan; in 2018, our company's total sales were 1.98 billion yuan, of which headquarters sales were 880 million yuan and branch sales is 1.1 billion yuan. In 2019, it achieved sales of 2.2 billion yuan. In order to speed up the company's development, the company has introduced CITIC Construction Investment to make the first round of strategic investment in the company; this year, six major investment banks such as Shenzhen Venture Capital, Gaoyuan Capital, Evergrande Life Insurance, and China Merchants Capital plan to make B-round investments. We are planned to introduce about a total 2 billion yuan from capital market in the next five years. Under the guidance of the national 13th Five-Year policy forHealthy of China, in the face of the marketing environment of great health, great medical care, and new generation of Internet, our company will introduce strategic capital and change the traditional business model, fully develop the industry of pharmaceutical chain retail , and break through the traditional philosophy and methods of pharmacy business , introduce a new generation of Internet and artificial intelligence platforms, create a "smart pharmacy" and "smart community family health service platform" with our own type. We plan to set up 10 branches in the whole province and even the whole country by 2022, add 3,500 retail chain pharmacies, and achieve a retail scale of 7 billion yuan.At that time,we will be listed on share stock A market or Hong Kong share stock market.


广东快乐十分下载软件